Trial Profile

A Phase II Trial of Tislelizumab in Combination With Sitravatinib for Recurrent/Metastatic Cervical Cancer After Platinum-Based Chemotherapy

Status: Withdrawn prior to enrolment

Phase of Trial: Phase II

Latest Information Update: 03 Jul 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Sitravatinib (Primary) ; Tislelizumab (Primary)
Indications Adenocarcinoma; Adenosquamous carcinoma; Cervical cancer; Squamous cell cancer
Focus Therapeutic Use
Acronyms ITTACC

Most Recent Events

28 Jun 2023 According to clinicaltrials.gov, the study was stopped: BeiGene has withdrawn their support owing to sitravatinib supply concerns. Mirati is ceasing further development of sitravatinib owing to the negative results of the SAPPHIRE trial which used sitravatinib in 2nd line met NSCLC setting.
28 Jun 2023 Status changed from not yet recruiting to withdrawn prior to enrolment.
31 Jan 2023 Planned initiation date changed from 1 Dec 2022 to 1 Mar 2023.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com